Stuttgart, 28.10.2024 - Admera Health LLC., a leading Next-Generation Sequencing (NGS) service provider located in South Plainfield, New Jersey, combining expert scientific support, advanced laboratory processes, stringent quality control measures, and proven quality project management, has acquired 100 percent of the shares in BioEcho Life Sciences GmbH. BioEcho Life Sciences GmbH is a developer and manufacturer with a focus on molecular biological and biochemical products and applications, particularly kits, reagents and biochemical solutions in the field of diagnostics, human and veterinary medicine, forensics, environmental and food analysis. With this strategic transaction, Admera Health LLC. intends to create a footprint in the European life sciences sector. Admera Health's expertise in handling difficult-to-sequence samples combined with BioEcho's cutting-edge extraction solutions will further realize Admera Health's mission to provide the best solutions for all researchers and biopharma companies ranging from exploratory to clinical. The parties involved have agreed not to disclose further details.
A CMS team led by lead partner Dr. Christoph Lächler provided comprehensive legal advice to Admera Health LLC. on the entire transaction. With regard to points of contact with US law, the CMS team has worked closely with Admera Health LLC.'s US-counsels of Magstone Law.
Press Contact
presse@cms-hs.com
